Prognosis and Timeline in ALS
The prognosis for ALS is poor, with an average life expectancy of 2 to 5 years from symptom onset and median survival of 30-39 months from onset or 19-31 months from diagnosis, though approximately 7% of patients survive beyond 5 years. 1, 2, 3
Disease Timeline and Key Milestones
The disease follows a predictable progression through specific milestones, though timing varies by individual progression rate:
From symptom onset:
- First consultation: 3.8 months 4
- Diagnosis: 8.0 months (occurs at ~35% through disease course) 4, 5
- Second body region involvement: 38% through disease course 5
- Employment changes: 16.2 months 4
- Walking aid requirement: 17.5 months 4
- Caregiver support initiation: 18.5 months 4
- Third region involvement: 61% through disease course 5
- Wheelchair dependence: 22.8 months 4
- Communication aid: 24.6 months 4
- Respiratory support (NIV): 27.3 months (at ~80% through disease course) 4, 5
- Gastrostomy feeding: 28.6 months (at ~77% through disease course) 4, 5
- Eye gaze technology: 29.7 months 4
- Care facility placement: 30.3 months 4
Prognostic Factors
Poor prognostic indicators that significantly shorten survival:
- Older age at onset (strongest predictor) 2, 3
- Female sex 3
- Bulbar onset (versus limb onset) 3
- Shorter time from symptom onset to diagnosis (indicates faster progression) 3
- Lack of marital partner 3
- Definite ALS at diagnosis (versus possible/probable) 2
- Poor physical health scores on SF-36 3
- Cognitive impairment (particularly frontotemporal dementia) - significantly shorter survival 6
Progression Rate Variations
Fast progressors reach all milestones significantly earlier than slow progressors. 4 The rapidly progressive nature means patients can develop catastrophic complications over very short timeframes, making the traditional healthcare reimbursement model inadequate for ALS. 1
Survival Statistics
- Median survival from onset: 32-39 months 2, 3
- Median survival from diagnosis: 19-31 months 2, 3
- 1-year survival from diagnosis: 78% 2
- 2-year survival from diagnosis: 56% 2
- 5-year survival from diagnosis: 7% 2, 3
Critical Clinical Implications
Most patients die from respiratory complications, making respiratory support decisions crucial for both quantity and quality of life. 1 The disease course is relentlessly progressive with no cure currently available, though multidisciplinary care has been shown to prolong survival and improve quality of life. 1, 6
Common pitfall: Delaying discussions about prognosis, advance directives, and end-of-life planning until late in disease course when communication may be severely impaired. These conversations should occur early, ideally within 5-10 months before anticipated death, though only 23-80% of patients actually have these discussions depending on geographic location. 6
The aggressive timeline—with most functional milestones occurring within 30 months of symptom onset—necessitates urgent, proactive management rather than reactive care. 4